The Stargate Initiative Launches
A New Era Of U.S. Economic Growth
— Starting with Healthcare
Disseminated on behalf of Rakovina Therapeutics. Please read disclaimer below.
AI infrastructure is getting a $500 billion injectioni, with medical innovation designated as the clear priority.
It’s a field Rakovina Therapeutics (TSX:RKV, OTC:RKVTF) is advancing – using the exclusive Deep Docking™ AI platform to accelerate drug discovery timelines from years to months.
Find out about this early opportunity below
Be the first to receive all Investment Trending news
“As this technology progresses, we will see diseases get cured at an unprecedented rate.”ii
- Sam Altman, Founder of OpenAI
Similar in scope to the Apollo missions to the moon or Eisenhower’s creation of the interstate highway system - the Stargate Initiative is shaping up to be one of the most transformative investments in U.S. history.
It’s certainly among one of the largest federal incentives. The completion of the Interstate Highway system, which spans over 46,000 miles, came in at around $129 billion.iii
Being first to plant the flag on moon came at a cost of only $25.8 billion – what would equate to around $318 billion when adjusted for inflation.iv
Much like the space race, advancing AI technologies is also one of the most critical incentives. With China’s recent DeepSeek release, the competition for AI dominance has never been more pressing.
That’s why $500 billion was earmarked to ensure the U.S. stays at the forefront of this technological revolution. Aimed at developing a robust AI infrastructure, the landmark initiative will guarantee companies have the funding they need to bring world-changing technology into the hands of American businesses and consumers.v
For industries like healthcare, the impact is expected to be dramatic.
Sam Altman, the founder of OpenAI, has long said that AI will revolutionize medicine, speeding up drug development and curing diseases at an unprecedented rate. That vision came into focus during the unveiling of Stargate, when Altman was given the clear directive to focus on healthcare.vi
Not the logistics of the endeavor… or data center infrastructure… or the funding model… The conversation revolved on to two key points: How AI would accelerate breakthroughs in medicine, and how soon we can expect to see tangible results.
Healthcare is at the top of the list when it comes to furthering the capabilities of AI.vii
We’ve already seen the beginnings of this transformation. Early AI models have been in use for years, helping doctors detect cancers earlier and more effectivelyviii, and in turn potentially leading to better treatment outcomes.
But the real shift will occur when AI can be relied on to discover new therapies for difficult to treat diseases, like cancer, that have thus far evaded a cure.
That’s where Rakovina Therapeutics (TSX:RKV,OTC:RKFTF) and the Deep Docking™ platform are breaking new ground.
Proven AI-Driven Drug Discovery
Rakovina Therapeutics is a biopharmaceutical research company harnessing the power of AI to aid in the development of novel cancer therapies.
The company has an exclusive license to operate the Deep Docking™ platform - a sophisticated tool developed by Rakovina’s Senior AI and Medicinal Chemistry Advisor, Dr. Artem Cherkasov, in collaboration with the University of British Columbia.
The Deep Docking™ platform is unique, in that it can screen billions of potential drug candidates at a fraction of the time and cost. It combines a large language model (LLM) for initial screening, with machine learning to determine which drug candidates are the most likely to succeed.
Where traditional drug discovery can take years to develop lead compounds, Deep Docking™ can screen billions of potential candidates in days to weeks.
The platform processes all known studies, trials, and data about any given molecule to deliver a 6,000-fold enrichment in drug candidate identification - with a 100-fold increase in efficiency compared to traditional methods.
Key benefits:
- High-Yield Discovery: Screens enormous chemical libraries to pinpoint the most promising candidates.
- Shortened Timelines: Achieves in months what would traditionally take years, drastically reducing the cost and risk associated with drug development.
- Maximized Success Rates: Predicts safety and efficacy with unparalleled precision.
Rakovina also collaborates with Variational AI for use of the Enki™ platform. Trained on more than 570 targets, across 10 target classes, Enki™ relies on generative algorithms to parse through decades worth of experimental data. This remarkable tool can then develop entirely new chemical structures that are tailored to specific targets.ix
Together, these AI platforms allow the company to discover and refine therapies faster and with greater accuracy than ever before.
Consider that it can take up to 14 yearsx and $2.6 billion on average for pharmaceutical companies to screen potential drugs, test them for efficacy, safety, and side effects, and finally bring them through FDA approval.xi And of the thousands of drug candidates that are tested annually, only 9% on average make it through the pipeline.xii
Rakovina Therapeutics (TSX:RKV, OTC:RKFTF) is working to de-risk this lengthy process. By analyzing the relationship between the biological activity of a molecule and its chemical structure, Deep Docking™ and Enki™ can help predict the biological effect of candidates in advance.xiii
The technology has already been field-tested.
An early version of the Deep Docking™ platform discovered a treatment for prostate cancer that sold to Roche Pharma for $141.7 million, in the largest IP deal ever done by the University of British Columbia.xiv
Under the direction of Rakovina Therapeutics, Deep Docking™ and Enki™ are now being used to tackle another challenge - identifying drug candidates that target a disorder common in 75% of all cancerous tumors.
Advancing Cancer Care With The Precision Of AI
While Rakovina’s platform has widescale application potential, the company is initially targeting cancers linked to DNA-Damage Response (DDR) molecules.
In a healthy system, these are compounds that repair DNA damage wherever it occurs throughout the body — whether from the sun, additives in food, or pollution.
But several factors can cause this system to fail. Three out of four solid tumor cancers are caused by a problem with DDR. As a result, the market for drugs that address DDR malfunctions is climbing quickly, expected to reach $18 billion by 2034.xv
This growing concern has led that pharmaceutical companies to invest a combined $25 billion into developing or acquiring potential drugs to treat DDR malfunctions.xvi
Merck paid $1.5 billion last October for a company working on this solution… and Novartis paid $1.2 billion for a similar drug that was still in the discovery phase — a candidate hadn’t even been decided on.xvii
First-generation DDR therapies have proven effective so far, but there’s still room for improvement. One of the main downsides is they often affect a number of enzymes — not just the ones targeted. This can lead to unintended side effects. They also have difficulty penetrating the blood-brain barrier, making them ineffective for brain cancers.
After screening billions of potential treatments, Rakovina Therapeutics (TSX:RKV,OTC:RKFTF) has developed a pipeline targeting DNA-Damage Response (DDR) mechanisms. In a matter of months, the company has accomplished what would take decades using traditional methods.
- The kt-2000AI Series are selective PARP-1 inhibitors targeting cancers with central nervous system metastases, with minimal off-target effects. PARP Inhibitors are a powerful class of cancer drugs that prevent cancer cells from repairing DNA damage, causing them to die off selectively while sparing healthy cells.xviii
- The kt-3000 Series are PARP and HDAC inhibitors aimed at treating resistant and aggressive cancers like breast, ovarian, and prostate cancers. These are a new class of drugs that are being developed to speed up the “catastrophic” phase for cancer cells, by switching off various key enzymes in DNA repair mechanisms.xix
These candidates are currently undergoing testingat the University of British Columbia — one of the best cancer research centersin the world.
Strategic Scientific Leadership
Rakovina Therapeutics is guided by experts in oncology, biotechnology, and drug discovery, with a proven track record of advancing cancer therapies from discovery to commercialization.
Leadership
- Jeffrey Bacha, BSC, MBA – Executive Chairman: 25 years of experience as founder and executive of multiple companies across the health sector such as Kintara Therapeutics (NASDAQ: KTRA), XBiotech, Inc. (NASDAQ: XBIT), Inimex Pharmaceuticals and Inflazyme Corp, a company that went from a $20 million market cap to $700 million in under a year.
- Mads Daugaard, PhD – President & CSO: Cancer biologist with >20 years of expertise in translational cancer research, DNA-damage response mechanisms, and therapeutics targeting DNA integrity. Dr. Daugaard was also Senior Research Scientist at Vancouver Prostate Centre, Associate Professor at University of British Columbia, Department of Urologic Sciences and Co-founder of VAR2 Pharmaceuticals and VarCT Diagnostics.
- Michelle Seltenrich, BSC, MBA - Director of Corporate Development: 23+ years accomplished executive in publicly traded biotech finance, operations, and business development. Ms. Seltenrich was the former Director of FP&A at Zymeworks and former VP of Operations at Sirona Biochem, where she negotiated a key AbbVie deal, boosting share price by 48%.
Scientific Advisory Board
- Artem Cherkasov, PhD – AI & Medicinal Chemistry Advisor: Professor at UBC's Department of Urologic Sciences and Senior Scientist at Vancouver Prostate Centre. Dr. Cherkasov has co-authored 200+ research papers, filed 80+ patents, and licensed 8 drug candidates to major companies as well as utilized AI-based platform, Deep Docking, to identify potential COVID-19 treatments, sharing findings with the scientific community.
- Petra Hamerlik, PhD – Professor, Chair of Translational Neuro-Oncology at the University of Manchester, UK. Dr Hamerlik was also former director and principal scientist at AstraZeneca, overseeing their DNA-damage response program.
With the average cost of developing a new drug reaching $2.6 billion, Rakovina could potentially save drug developers billions of dollars and move therapies to market faster than traditional methods.
The company has an exclusive licensing agreement to the Deep Docking AI program… a pipeline of potential drug candidates undergoing testing … and a team with a strong track record of successfully growing pharmaceutical companies.
And this coming April, Rakovina is hoping to present their first findings to one of the largest cancer conferences in the world.
Visit the company
website or sign up with your email below to learn more about
Rakovina Therapeutics (TSX:RKV,OTC:RKVTF).
Rakovina Therapeutics
(TSX:RKV, OTC:RKVTF)
Featured In
Recent Press Releases
Be the first to receive all Investment Trending news
ihttps://www.forbes.com/sites/garthfriesen/2025/01/23/trumps-ai-push-understanding-the-500-billion-stargate-initiative/
iihttps://www.cbsnews.com/news/trump-announces-private-sector-ai-infrastructure-investment/
iiihttps://www.archives.gov/publications/prologue/2006/summer/interstates.html
ivhttps://taxfoundation.org/blog/apollo-moon-space-race-industrial-policy-cost/#:~:text=Though%20a%20historical%20accomplishment%2C%20the,the%20US%20at%20the%20time.
vhttps://www.forbes.com/sites/garthfriesen/2025/01/23/trumps-ai-push-understanding-the-500-billion-stargate-initiative/
vihttps://www.cbsnews.com/news/trump-announces-private-sector-ai-infrastructure-investment/
viihttps://www.cbsnews.com/news/trump-announces-private-sector-ai-infrastructure-investment/
viiihttps://www.aamc.org/news/it-cancer-artificial-intelligence-helps-doctors-get-clearer-ixpicture#:~:text=The%20AI%20model%20recognizes%20patterns,to%20assess%20the%20cancer%20risk. https://variational.ai/#company
xhttps://ncats.nih.gov/research/research-activities/ntu#:~:text=Therapeutic%20development%20is%20a%20costly,be%20%241%20billion%20or%20more.
xihttps://www.policymed.com/2014/12/a-tough-road-cost-to-develop-one-new-drug-is-26-billion-approval-rate-for-drugs-entering-clinical-de.html xiihttps://archive.bio.org/media/press-release/new-study-shows-rate-drug-approvals-lower-previously-reported
xiiihttps://www.rakovinatherapeutics.com/wp-content/uploads/2025/01/Rakovina_Investor_Deck_Q12025.pdf
xivhttps://vancouversun.com/business/massive-cancer-drug-deal-one-of-ubcs-biggest-to-date
xvhttps://www.precedenceresearch.com/dna-repair-drugs-market
xvihttps://www.rakovinatherapeutics.com/wp-content/uploads/2025/01/Rakovina_Investor_Deck_Q12025.pdf
xviihttps://www.rakovinatherapeutics.com/wp-content/uploads/2025/01/Rakovina_Investor_Deck_Q12025.pdf
xviiihttps://www.rakovinatherapeutics.com/kt-2000ai/
xixhttps://www.rakovinatherapeutics.com/kt-3000/
IMPORTANT NOTICE AND DISCLAIMER
This article is a paid advertisement. Think Ink Marketing and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by profiled companies or third parties to organize marketing campaigns, which include the creation and dissemination of these types of communications. In this case, in an effort to enhance public awareness of Rakovina Therapeutics Inc. (“RKVTF”) and its securities, RKVTF has provided the Publisher with a budget of approximately $165,000 USD to cover the costs associated with the creation and distribution of this communication. The Publisher may retain any excess sums after expenses as its compensation. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by (RKVTF) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP.
The Publisher does not own any shares of RKVTF and has no information concerning share ownership by others of in RKVTF. The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
.FORWARD LOOKING STATEMENTS.
This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to RKVTF’s industry; (b) market opportunity; (c) RKVTF’s business plans and strategies; (d) services that RKVTF intends to offer; (e) RKVTF’s milestone projections and targets; (f) RKVTF’s expectations regarding receipt of approval for regulatory applications; (g) RKVTF’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) RKVTF’s expectations regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute RKVTF’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) RKVTF’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) RKVTF’s ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) RKVTF’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of RKVTF to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) RKVTF operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact RKVTF’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing RKVTF’s business operations (e) RKVTF may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
INDEMNIFICATION/RELEASE OF LIABILITY.
By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY.
Capital Trends is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
IMPORTANT NOTICE AND DISCLAIMER
This website is owned and hosted by Think Ink Marketing. Articles appearing on this website should be considered paid advertisements. Think Ink Marketing and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Website Host has not been compensated by any of the profiled companies. The Website Host’s compensation for articles appearing on this website is as follows: The Website Host has been paid approximately $500 per month while the advertisement campaign is active by Think Ink Marketing as compensation to host the article profiling Rakovina Therapeutics Inc. (“RKVTF”).
SHARE OWNERSHIP
The Website Host does not own any shares of any profiled companies and has no information concerning share ownership by others of any profiled companies. The Website Host cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
NO SECURITIES OFFERED
The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of RKVTF or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about RKVTF Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in RKVTF’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Website Host, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
LINKS TO THIRD PARTY WEBSITES
This website enables users to link to external websites not under the control of The Website Host. The Website Host has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Website Host expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.
INTELLECTUAL PROPERTY
Think Ink Marketing is the Website Host’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Website Host is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Website Host to any rights in any third-party trademarks.
FORWARD LOOKING INFORMATION
This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect expectations regarding RKVTF’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to RKVTF’s industry; (b) market opportunity; (c) RKVTF’s business plans and strategies; (d) services that RKVTF intends to offer; (e) RKVTF’s milestone projections and targets; (f) RKVTF’s expectations regarding receipt of approval for regulatory applications; (g) RKVTF’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) RKVTF’s expectations regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute RKVTF’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) RKVTF’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) RKVTF’s ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) RKVTF’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of RKVTF to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) RKVTF’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact RKVTF’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing RKVTF’s business operations (e) RKVTF may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
HISTORICAL INFORMATION
Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of RKVTF or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of RKVTF or such entities and are not necessarily indicative of future performance of RKVTF or such entities.
